---
title: "JAN (NYSE:JAN) Receives Consensus Recommendation of \"Buy\" from Analysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282689077.md"
description: "Shares of JAN (NYSE:JAN) have received an average \"Buy\" rating from seven analysts, with a twelve-month price target averaging $27.14. Recent coverage includes upgrades and target prices from various brokerages, with KeyCorp and Morgan Stanley setting targets at $28.00. Insider purchases have increased significantly, with directors acquiring a total of 187,000 shares valued at $3.74 million in the last quarter. The stock opened at $24.00, with a market cap of $6.16 billion and a P/E ratio of -62.29, indicating potential volatility."
datetime: "2026-04-14T12:12:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282689077.md)
  - [en](https://longbridge.com/en/news/282689077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282689077.md)
---

# JAN (NYSE:JAN) Receives Consensus Recommendation of "Buy" from Analysts

Shares of JAN (NYSE:JAN - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $27.1429.

Several brokerages recently commented on JAN. Wall Street Zen upgraded shares of JAN to a "hold" rating in a research note on Saturday, April 4th. KeyCorp started coverage on shares of JAN in a research report on Tuesday. They set an "overweight" rating and a $28.00 target price for the company. BNP Paribas Exane started coverage on shares of JAN in a research report on Tuesday. They set an "outperform" rating and a $27.00 target price for the company. Barclays started coverage on shares of JAN in a research report on Tuesday. They set an "overweight" rating and a $26.00 target price for the company. Finally, Morgan Stanley started coverage on shares of JAN in a research report on Tuesday. They set an "overweight" rating and a $28.00 target price for the company.

**Check Out Our Latest Research Report on JAN**

## Insider Activity at JAN

In other news, Director Charles J. Herman, Jr. purchased 5,500 shares of the stock in a transaction dated Monday, March 23rd. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $110,000.00. Following the completion of the acquisition, the director directly owned 13,000 shares in the company, valued at $260,000. This represents a 73.33% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John V. Arabia purchased 60,000 shares of the stock in a transaction dated Monday, March 23rd. The shares were purchased at an average price of $20.00 per share, with a total value of $1,200,000.00. Following the completion of the acquisition, the director owned 67,500 shares of the company's stock, valued at approximately $1,350,000. This represents a 800.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 187,000 shares of company stock valued at $3,740,000 in the last quarter. 3.00% of the stock is owned by corporate insiders.

## JAN Stock Up 0.6%

Shares of NYSE JAN opened at $24.00 on Tuesday. JAN has a 52 week low of $22.76 and a 52 week high of $24.36. The stock has a market capitalization of $6.16 billion, a P/E ratio of -62.29 and a beta of 2.16.

## Key JAN News

Here are the key news stories impacting JAN this week:

-   Positive Sentiment: Cantor Fitzgerald initiated coverage with an Overweight rating and a $27 price target, which can prompt buying interest from investors and funds looking for analyst-backed ideas. Benzinga
-   Neutral Sentiment: Technical/context: JAN’s 12‑month trading range is narrow ($22.76–$24.36) and the stock recently opened near $24.00, so upside from new coverage could be constrained unless momentum or fundamentals shift.
-   Neutral Sentiment: Risk/volatility note: market cap ~$6.16B with a negative P/E (-62.29) and a beta of 2.16 — the name can be volatile and sensitive to sentiment and analyst flows rather than steady earnings multiples.

## About JAN

(Get Free Report)

Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025.

## Further Reading

-   Five stocks we like better than JAN

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in JAN Right Now?

Before you consider JAN, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and JAN wasn't on the list.

While JAN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [JAN.US](https://longbridge.com/en/quote/JAN.US.md)
- [KEY.US](https://longbridge.com/en/quote/KEY.US.md)
- [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MKTW.US](https://longbridge.com/en/quote/MKTW.US.md)
- [KEY-K.US](https://longbridge.com/en/quote/KEY-K.US.md)
- [KEY-L.US](https://longbridge.com/en/quote/KEY-L.US.md)
- [KEY-J.US](https://longbridge.com/en/quote/KEY-J.US.md)
- [KEY-I.US](https://longbridge.com/en/quote/KEY-I.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [This SanDisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/282686213.md)
- [Should You Buy the Dip in Palo Alto Networks Stock Today?](https://longbridge.com/en/news/282551657.md)
- [Down 7% from Its All-Time Highs, Should You Buy the Dip in JPMorgan Stock?](https://longbridge.com/en/news/282840256.md)
- [Tecogen (TGEN) Gets a Buy from Craig-Hallum](https://longbridge.com/en/news/282553656.md)
- [Capricor Therapeutics (CAPR) Gets a Buy from Roth MKM](https://longbridge.com/en/news/282746660.md)